

# Trial NL80852.028.22

Published: 07-09-2022

Last updated: 28-03-2024

Publication withdrawn by sponsor

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruiting
<b>Health condition type</b>	Gastrointestinal inflammatory conditions
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON53829

### Source

ToetsingOnline

### Brief title

n.a.

### Condition

- Gastrointestinal inflammatory conditions

### Synonym

Publication withdrawn by sponsor

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Publication withdrawn by sponsor

**Source(s) of monetary or material Support:** Publication withdrawn by sponsor

### Intervention

**Keyword:** Publication withdrawn by sponsor

## Outcome measures

### Primary outcome

Publication withdrawn by sponsor

### Secondary outcome

Publication withdrawn by sponsor

## Study description

### Background summary

Publication withdrawn by sponsor

### Study objective

Publication withdrawn by sponsor

### Study design

Publication withdrawn by sponsor

### Intervention

Publication withdrawn by sponsor

### Study burden and risks

Publication withdrawn by sponsor

## Contacts

### Public

Publication withdrawn

NL

### Scientific

Publication withdrawn

## Trial sites

### Listed location countries

Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, India, Israel, Italy, Japan, Jordan, Korea (the Republic of), Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan (Province of China), Turkey, United Kingdom, United States of America

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Publication withdrawn by sponsor

### Exclusion criteria

Publication withdrawn by sponsor

## Study design

### Design

Study phase:	2
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)

Control:	Placebo
Primary purpose:	Treatment

## Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	12-04-2023
Enrollment:	18
Type:	Actual

## Medical products/devices used

Registration:	No
---------------	----

## Ethics review

Approved WMO	
Date:	14-12-2022
Application type:	First submission
Review commission:	METC Brabant (Tilburg)
Approved WMO	
Date:	12-01-2023
Application type:	Amendment
Review commission:	METC Brabant (Tilburg)
Approved WMO	
Date:	28-03-2023
Application type:	Amendment
Review commission:	METC Brabant (Tilburg)
Approved WMO	
Date:	23-06-2023
Application type:	Amendment
Review commission:	METC Brabant (Tilburg)
Approved WMO	
Date:	23-08-2023
Application type:	Amendment
Review commission:	METC Brabant (Tilburg)

Approved WMO	
Date:	09-10-2023
Application type:	Amendment
Review commission:	METC Brabant (Tilburg)
Approved WMO	
Date:	09-02-2024
Application type:	Amendment
Review commission:	METC Brabant (Tilburg)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
EudraCT	2021-003314-39
CCMO	NL80852.028.22